QRA 244
Alternative Names: QRA-244; QRL-101Latest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Developer QurAlis Corporation
- Class Neuroprotectants; Small molecules
- Mechanism of Action KCNQ2 potassium channel stimulants; KCNQ3 potassium channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis; Epilepsy